Impact of biomarkers on clinical trial risk

Monday, October 7, 2013 - 2:30pm

Impact of biomarkers on clinical trial risk.

Reid GGBin Yameen TAParker JL.

Source

Department of Biology, University of Toronto Mississauga, Mississauga, ON, Canada.

Abstract

The last decade has witnessed the cost of drug development rise dramatically; concurrently, the number of new drug approvals has declined. Clinical trial failure rates have contributed significantly to this 'innovation' crisis and are directly related to clinical trial risk. One strategy that is often touted to resolve this challenge depends on embracing a personalized medicine approach where treatment is tailored to a patient's unique genetic background. We highlight a new risk-based paradigm of clinical trial risk that evaluates the utility of biomarkers in drug development and their riskmitigation benefits. Furthermore, examples elucidating the current state of biomarker integration during clinical trials and the potential risks posed by doing so will be discussed.

Published in Pharmacogenomics.

Dr. Jayson Parker, Medical Biotechnology Analyst with the Master of Biotechnology Program (MBiotech) conducted the study with Tarek Bin-Yameen (MBiotech Class of 2014) and Geoff Reid (MBiotech Class of 2013).

For more information, please contact:

Jayson Parker
University of Toronto at Mississauga
jayson.parker@utoronto.ca